Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type

NCT00861120 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Pegylated liposomal doxorubicin
DRUG: Panitumumab

Sponsor

Vejle Hospital